Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2014-11-14 Interim / Quarterly Rep…
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Communication relating to accounts, results, and turnover
Interim / Quarterly Report Classification · 95% confidence The document is a press release announcing the revenue for the third quarter of 2014. It contains specific financial tables (Income statement at September 30, 2014) and a narrative discussion of the company's activity during that period. Since it provides substantive financial data for a quarterly period, it qualifies as an Interim/Quarterly Report (IR) rather than just an earnings release (ER) or a report publication announcement (RPA). Q3 2014
2014-11-14 English
Communiqués au titre de l'obligation d'information permanente / Communiqué sur comptes, résultats, chiffres d’affaires
Earnings Release Classification · 100% confidence The document is a press release from Nanobiotix announcing its revenue for the third quarter of 2014. It includes specific financial tables detailing revenue figures for the quarter and the nine-month period, along with management commentary on business activities and operational updates. Since it provides the initial announcement of quarterly financial results with key highlights rather than a full comprehensive interim report, it is classified as an Earnings Release (ER). Q3 2014
2014-11-14 French
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital) and explicitly references Article 223-16 of the AMF (Autorité des Marchés Financiers) General Regulation. It provides a table detailing the total number of shares and voting rights as of October 31, 2014. This type of regular disclosure regarding the total share capital and voting rights is a specific regulatory requirement, often related to major shareholdings or capital structure updates, but the most precise fit among the provided codes for a routine notification about the total number of shares/voting rights is related to share capital changes or major holdings. Since it is a monthly update on the total number of shares and voting rights, it directly relates to the composition of the share capital. While 'MRQ' (Major Shareholding Notification) deals with crossing thresholds, this document reports the absolute total, which is a prerequisite for MRQ filings. However, the closest category that covers changes or updates related to the share structure itself, especially when reported monthly, is 'SHA' (Share Issue/Capital Change) or potentially 'RNS' (Regulatory Filings) if no better fit exists. Given the content is a direct report on the total number of shares and voting rights, which is a fundamental aspect of the capital structure, 'SHA' is a strong candidate, although 'MRQ' often encompasses these disclosures in practice. Looking closely at the definitions, 'SHA' is for 'New share issues, stock splits, or other capital changes.' This document reports the *current state* of the capital, not necessarily a change event, but it is a mandatory disclosure tied to the capital base. 'MRQ' is for 'Notification of changes in significant share ownership levels (crossing thresholds).' Since this is a mandatory monthly disclosure of the *total* capital base, and not specifically a notification of a shareholder crossing a threshold, 'SHA' or 'RNS' are better. Given the French regulatory context (AMF), these monthly capital structure reports are often filed under general disclosure rules. Since it is a specific, recurring regulatory disclosure about the capital base, and not a general announcement, I will classify it as a specific regulatory filing related to capital structure. 'SHA' covers capital changes, and this is a report on the capital base. If it were a notification of a shareholder crossing a threshold, it would be MRQ. Since it is a mandatory report on the total number of shares/voting rights, it fits best under the general category of capital structure reporting, which aligns most closely with 'SHA' or the fallback 'RNS'. Given the highly specific nature of the content (total voting rights), and the lack of a dedicated 'Total Capital Disclosure' code, 'RNS' (General regulatory announcements and fallback) is the safest classification for a routine, non-event-driven regulatory filing that doesn't fit the other specific event codes (like DIV, CAP, SHA). However, because it is explicitly about the *number of shares* and *voting rights*, it is fundamentally a capital structure report. I will lean towards 'SHA' as the most relevant structural category, acknowledging it's a status report rather than an event announcement. Reconsidering the options: This is a mandatory disclosure of the total share capital count, which is a fundamental component of capital structure reporting. 'SHA' is for changes, but reporting the current state is often bundled. 'RNS' is the fallback. I will use 'RNS' as it is a routine, non-event-driven regulatory filing that doesn't fit the specific event codes like DIV, CAP, or SHA (which implies an *action* like an issue or split). The document is short (3357 chars) and is a direct regulatory filing, fitting the RPA/RNS rule, but it is the report itself, not an announcement *of* a report. Therefore, RNS is the most appropriate fallback for a routine regulatory disclosure not covered elsewhere. I assign a high confidence score due to the clear regulatory reference (AMF Article 223-16).
2014-11-05 French
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 92% confidence The document is a press release dated October 16, 2014, announcing that Nanobiotix has received authorization from the French regulatory agency (ANSM) to start its Phase II/III registration trial for NBTXR3 in Soft Tissue Sarcoma in Europe. It details the study protocol, objectives (primary, secondary, exploratory), and provides background on the disease and the product. This type of announcement, detailing clinical trial progress, regulatory milestones, and future plans, is characteristic of an Earnings Release (ER) or a general corporate update. Since it focuses on a major clinical development milestone rather than just summarizing quarterly financial figures (which would be ER) or providing a full management discussion (MDA), and it is a formal announcement of a significant corporate event, it aligns best with an Earnings Release (ER) if it were tied to a reporting period, or a general Regulatory Filing (RNS) if it were purely regulatory. However, given the structure—a headline announcement followed by detailed clinical/product information and contact details—it functions as a key corporate update. In the context of the provided definitions, this is a significant corporate announcement regarding product development and regulatory progress, which often accompanies or substitutes for a formal Earnings Release in biotech/pharma, or it could be classified as a general Regulatory Filing (RNS) if it doesn't fit other specific categories. Since it is a detailed announcement of a major clinical trial initiation, which is a key operational/financial driver, and it is not a transcript (CT), a formal report (10-K, IR), or a proxy statement (DEF 14A), the closest fit among the options that cover significant corporate news is often the Earnings Release (ER) category for major operational updates, or RNS as a catch-all. Given the focus on a clinical trial authorization, which is a critical operational milestone, and the lack of explicit quarterly financial summary, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback for a specific clinical development press release that isn't a full financial report or transcript.
2014-10-16 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Regulatory Filings Classification · 95% confidence The document is a press release dated October 16, 2014, announcing that Nanobiotix received approval to start a Phase II/III registration trial for its product NBTXR3 in Europe. It details the trial design, objectives, and future plans. This type of announcement, which communicates significant operational or clinical development milestones to the public and investors, is characteristic of an Earnings Release (ER) if it were tied to financial results, or more generally, a Regulatory Filing (RNS) if it's a broad announcement. However, given the content focuses on clinical trial progress and regulatory milestones (ANSM approval), it is a significant corporate update. Since it is not a full financial report (10-K, IR), a transcript (CT), or a specific management/board change (MANG), the most appropriate general category for a major, non-financial, regulatory/clinical update press release that doesn't fit other specific categories is often the general Regulatory Filings category (RNS). It is not an Earnings Release (ER) as it does not contain financial results, nor is it a Report Publication Announcement (RPA) as it is the news itself, not an announcement *about* another report being published. Therefore, RNS is the best fit as a general regulatory/corporate announcement.
2014-10-16 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Capital/Financing Update Classification · 95% confidence The document is a press release dated October 13, 2014, announcing that Nanobiotix received a second payment from Bpifrance related to the NICE project for the development of NBTXR3 in liver cancers. It details funding milestones, ongoing non-clinical work, and provides background information on the NICE consortium and the company itself. This type of announcement, focusing on specific operational or financial milestones (like receiving grant money or achieving a development stage) outside of routine quarterly/annual reporting, best fits the category for general regulatory announcements or news releases that don't map to specific financial reports (10-K, IR, ER) or corporate actions (DIV, CAP, MANG). Given the options, it is a specific corporate update that is not a formal financial report, a management discussion, an earnings release, or a capital event. It is a general announcement of progress. Since it is not explicitly an announcement *of* a report (RPA) or a director's dealing (DIRS), the most appropriate general category for a significant, non-standard corporate update that doesn't fit elsewhere is Regulatory Filings (RNS), which serves as a broad category for miscellaneous official announcements.
2014-10-13 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.